The use of noben for correction of mitochondrial disorders in Friedrich's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 107, Issue 9, 2007, Pages 32-37

  Ershova, M V ^a   Illarioshkin, S N ^a   Sukhorukov, V S ^a  

^a NONE

Author keywords

Friedrich's disease; Idebenon; Mitochondrial disorders; Noben; Treatment

Indexed keywords

EID: 38149017855     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Babcock M., De Silva D., Oaks R. et al. Regulation of mitochondrial iron accumulation by Yfhlp, a putative homolog of Frataxin. Science 1997; 276: 1709-1712.
9. Buyse G., Mertens L., Di salvo G. et al. Idebenone treatment in Friedreich's ataxia: neurological, cardiac and biochemical monitoring. Neurology 2003; 60: 1679-1681.
10. Campuzano V., Montermini L., Koutnikova H. et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996; 271: 1423-1427.
11. Campuzano V., Montermini L., Lutz Y. et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997; 6: 1771-1780.
12. Chakravarty A. Friedreich's ataxia - yesterday, today and tomorrow. Neurol India 2003; 51: 176-182.
13. De Michele G., Copolla G., Cocozza S., Filla A. A pathogenetic classification of hereditary ataxias: Is the time ripe? J Neurol 2004; 251: 913-922.
14. Delatycki M.B., Williamson R., Forrest S.M. Friedreich ataxia: an over-view. J Med Genet 2000; 37: 1-8.
15. DiMauro S., Moraes C. T. Mitochondrial encephalomyopathies. Arch Neurol 1993; 50: 1197-1208.
16. DiMauro S., Schon E.A. Mitochondrial respiratory-chain diseases. New Engl J Med 2003; 348: 2656-2668.
17. Dürr A., Cossee M., Agid Y. et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996; 335: 1169-1175.
18. Filla A., Cocozza S., De Michele G. Friedreich's ataxia: from the patient to the gene. Neurol Sci 2001; 22: 21-25.
19. Filla A., De Michele G. Prevalence of herediatary ataxias and spastic paraplegias in Molise, a region of Italy. J Neurol 1992; 239: 351-353.
20. Filla A., De Michele G., Cavalcanti F. et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996; 59: 554-560.
21. Filla A., Moss A.J. Idebenone for treatment of Friedreich's ataxia? Neurology 2003; 60: 1569-1570.
22. Geoffroy G., Barbeau A., Breton G. el al. Clinical description and roentgenologic evaluation of patients with Friedreich's ataxia. Can J Neurol Sci 1976; 3: 279-286.
23. Geromel V., Darin N., Chretien D. et al. Coenzyme Q10 and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metabol 2002; 77: 21-30.
24. Harding A.E. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981; 104: 598-620.
25. Harding A.E. The hereditary ataxias and related disorders. Edinburgh: Churchill Livingstone 1984.
26. Hausse A. O., Aggoun Y., Bonnet D. et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002; 87: 346-349.
27. Koutnikova H., Campuzano V., Foury F. et al. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet 1997; 16: 345-351.
28. Lodi R., Cooper J., Bradley J. et al. Deficit of in vivo mitochondrial ATP production in patient with Friedreich ataxia. Proc Nat Acad Sci USA 1999 96; 11492-11495.
29. Lynch D.R., Farmer J.M., Baker L.J., Wilson R.B. Friedreich ataxia. Effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 2002; 59: 743-747.
30. Mariotti C., Solari A., Torta D. et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003; 60: 1676-1679.
31. Pandolfo M. Molecular genetics and pathogenesis of Friedreich ataxia. Neuromusc Dis 1998; 8: 409-415.
32. Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch Neurol 1999; 56: 1201-1208.
33. Peterson P.L. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta 1995; 1: 275-280.
34. Rötig A., De Lonlay P., Chretien D. et al. Frataxin gene expansion causes aconitase and mitochondrial iron-sulfur protein deficiency in Friedreich ataxia. Nat Genet 1997; 17: 215-217.
35. Rustin P. The use of antioxidants in Friedreich's ataxia treatment. Exp Opin Investig Drugs 2003; 12: 569-575.
36. Rustin P., Bonnet D., Rotig A. et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2004; 62: 524-525.
37. Rustin P., von Kleist-Retzow J.C., Chantrel-Groussard K. et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999; 354: 477-479.
38. Schapira A.H.V. Mitochondrial disorders. Curr Opin Neurol 1997: 10: 43-47.
39. Schapira A.H.V. Mitochondrial involvement in Parkinson's disease, hereditary spastic paraplegia and Friedreich's ataxia. Bioch Bioph Acta 1999; 1410: 159-170.
40. Schulz J.B., Dehmer T., Schals L. et al. Oxidative stress in patients with Friedreich's ataxia. Neurology 2000; 55: 1719-1721.
41. Seznec H., Simon D., Monassier L. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 2004; 13: 1017-1024.
42. Sherer T., Greenamyre J.T. A therapeutic target and biomarker in Friedreich's ataxia. Neurology 2000; 55: 1601-1602.
43. Wilson R.B., Roof D.M. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat Genet 1997; 16: 352-357.